WCN26-6177 Toward Immunosuppressant-Free Induction Therapy for Proliferative Lupus Nephritis: A Telitacicept-Based Case Report

Read full text Summarise with VIRAT
Authors: Qing Yan Jiang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Conventional induction therapy for proliferative lupus nephritis (PLN) requires high-dose glucocorticoids combined with immunosuppressants (e.g., cyclophosphamide or mycophenolate), which carries substantial risks of infections, poor adherence, and gonadotoxicity – a critical concern for reproductive-age patients. Telitacicept, a novel BLyS/APRIL dual-targeting fusion protein, may offer a safer alternative by selectively modulating B-cell pathways without broad immunosuppression, while preclinical studies indicate no adverse effects on fertility or embryo-fetal development.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106259–106259
Publication date
25 March 2026
Language
EN